Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 14;15(1):51.
doi: 10.1186/s12969-017-0178-9.

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Ekaterina I Alexeeva  1   2   3 , Leyla S Namazova-Baranova  4 , Tatyana M Bzarova  4   5 , Saniya I Valieva  4 , Rina V Denisova  4 , Tatyana V Sleptsova  4 , Kseniya B Isaeva  4 , Alexandra M Chomahidze  4 , Nikolay I Taibulatov  4 , Anna N Fetisova  4 , Anna V Karaseva  4 , Alexandr A Baranov  4
Affiliations

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Ekaterina I Alexeeva et al. Pediatr Rheumatol Online J. .

Abstract

Background: The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.

Methods: A total of 197 juvenile patients were enrolled in this study. Response to therapy was assessed using the ACRPedi 30/50/70/90 criteria, the Wallace criteria, and the Juvenile Arthritis Disease Activity Score 71 (JADAS-71). Univariate and multivariate logistic regression analyses were performed to identify potential baseline factors associated with treatment response in different JIA categories.

Results: One year after treatment initiation, 179 (90.9%) patients achieved ACRPedi30; 177 (89.8%) patients achieved ACRPedi50; 168 (85.3%) patients achieved ACRPedi70; and 135 (68.5%) patients achieved ACRPedi90 response. A total of 132 (67.0%) and 92 (46.7%) patients achieved inactive disease according to the Wallace criteria and the JADAS-71 cut-off point, respectively. Excellent response (achieving ACRPedi90 and clinically inactive disease according both to the Wallace criteria and the JADAS71 cut-off point) was associated with persistent oligoarticular JIA category, shorter disease duration before the start of etanercept, a lower number of DMARDs used before the introduction of etanercept, a lower number of joints with limited motion, and lower C-reactive protein at baseline. Poor response (failure to achieve ACR 70 or active disease according to both the Wallace criteria and JADAS71 even when ACR 70 was achieved) was associated with the polyarticular or enthesitis-related JIA categories, higher disease duration before the start of etanercept, and older age at disease onset.

Conclusion: Almost half (45.7%) of the patients who initiated etanercept treatment achieved an excellent response (inactive disease and ACRPedi90) after 1 year. What may be novel is our finding that the response to etanercept therapy was strongly associated with the JIA category. The response to etanercept therapy was also associated with the disease duration before the start of etanercept treatment.

Keywords: Anti-TNF treatment; Etanercept; Factors associated with treatment response; Juvenile idiopathic arthritis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of responses to etanercept in different JIA categories within 12 months after beginning treatment
See this image and copyright information in PMC

References

    1. Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2008;6:11. doi: 10.1186/1546-0096-6-11. - DOI - PMC - PubMed
    1. Kahn P. Juvenile idiopathic arthritis - an update on pharmacotherapy. Bull NYU Hosp Jt Dis. 2011;69:264–276. - PubMed
    1. Overall incidence in children in Russia (under age of 14 years) in 2011. Report of the Russian Federation Ministry of Health; 2015. https://static-3.rosminzdrav.ru/system/attachments/attaches/000/015/822/....
    1. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499–2512. doi: 10.1002/art.38092. - DOI - PMC - PubMed
    1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–82. doi:10.1002/acr.20460. - PMC - PubMed

MeSH terms